Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma

© The Author(s), 2024. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work wit...

Descripción completa

Detalles Bibliográficos
Autores: Martín-Broto, Javier, Olarte-García, Alicia, Fernandéz-Rodríguez, Ricardo, Ribeiro Ferreira, Marta, Carrasco-García, Irene, Galvez-Montosa, Fernando, Rincón-Pérez, Inmaculada, Peinado-Serrano, Javier, Azinovic, Ignacio, Guzmán-Gómez, Laura, Salgado, Lurdes, Sevillano, Alberto, Ortega, Justo, Alvarez, Cristina, Gutiérrez, Antonio, Moura, David S., Hindi, Nadia
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/360232
Acceso en línea:http://hdl.handle.net/10261/360232
Access Level:acceso abierto
Palabra clave:Durable response
Leiomyosarcoma
Soft tissue sarcomas
Trabectedin
id ES_a8f91cc9eecc8a558985f6ddbf17fd5e
oai_identifier_str oai:digital.csic.es:10261/360232
network_acronym_str ES
network_name_str España
repository_id_str
spelling Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcomaMartín-Broto, JavierOlarte-García, AliciaFernandéz-Rodríguez, RicardoRibeiro Ferreira, MartaCarrasco-García, IreneGalvez-Montosa, FernandoRincón-Pérez, InmaculadaPeinado-Serrano, JavierAzinovic, IgnacioGuzmán-Gómez, LauraSalgado, LurdesSevillano, AlbertoOrtega, JustoAlvarez, CristinaGutiérrez, AntonioMoura, David S.Hindi, NadiaDurable responseLeiomyosarcomaSoft tissue sarcomasTrabectedin© The Author(s), 2024. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Sage and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).Background and objectives: Dimensional response is an unmet need in second lines of advanced soft tissue sarcomas (STS). Indeed, the three approved drugs, pazopanib, trabectedin, and eribulin, achieved an overall response rate (ORR) of less than 10%. This fact potentially hinders the options for fast symptomatic relief or surgical rescue. The combination of trabectedin plus low-dose radiation therapy (T-XRT) demonstrated a response rate of 60% in phase I/II trial, while real-life data achieved 32.5% ORR, probably due to a more relaxed timing between treatments. These results were obtained in progressing and advanced STS. In this study, the merged databases (trial plus real life) have been analyzed, with a special focus on leiomyosarcoma patients. Design and methods: As responses were seen in a wide range of sarcoma histologies (11), this study planned to analyze whether leiomyosarcoma, the largest subtype with 26 cases (30.6%) in this series, exhibited a better clinical outcome with this therapeutic strategy. In addition, four advanced and progressing leiomyosarcoma patients, all with extraordinarily long progression-free survival of over 18 months, were collected. Results: A total of 847 cycles of trabectedin were administered to 85 patients, with the median number of cycles per patient being 7 (1–45+). A trend toward a longer progression-free survival (PFS) was observed in leiomyosarcoma patients with median PFS (mPFS) of 9.9 months [95% confidence interval (CI): 1.1–18.7] versus 5.6 months (95% CI: 3.2–7.9) for the remaining histologies, p = 0.25. When leiomyosarcoma and liposarcoma were grouped, this difference reached statistical significance, probably due to the special sensitivity of myxoid liposarcoma. The mPFS for L-sarcomas was 12.7 months (95% CI: 7–18.5) versus 4.3 months (95% CI: 3.3–5.3) for the remaining histologies, p = 0.001. Cases with long-lasting disease control are detected among leiomyosarcoma patients. Conclusion: Even when extraordinarily long-lasting responses do exist among leiomyosarcoma patients treated with T-XR, we were unable to demonstrate a significant difference favoring leiomyosarcoma patients in clinical outcomes.The present study was funded by PharmaMar.Peer reviewedSage PublicationsPharmaMarMartín-Broto, Javier [0000-0001-7350-6916]Moura, David S. [0000-0002-6514-2419]Hindi, Nadia [0000-0002-5864-762X]Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202420242024info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/360232reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésThe underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.1177/17588359231225044https://doi.org/10.1177/17588359231225044Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3602322026-05-22T06:33:51Z
dc.title.none.fl_str_mv Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
title Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
spellingShingle Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
Martín-Broto, Javier
Durable response
Leiomyosarcoma
Soft tissue sarcomas
Trabectedin
title_short Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
title_full Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
title_fullStr Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
title_full_unstemmed Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
title_sort Trabectedin and low-dose radiation therapy in patients with advanced leiomyosarcoma
dc.creator.none.fl_str_mv Martín-Broto, Javier
Olarte-García, Alicia
Fernandéz-Rodríguez, Ricardo
Ribeiro Ferreira, Marta
Carrasco-García, Irene
Galvez-Montosa, Fernando
Rincón-Pérez, Inmaculada
Peinado-Serrano, Javier
Azinovic, Ignacio
Guzmán-Gómez, Laura
Salgado, Lurdes
Sevillano, Alberto
Ortega, Justo
Alvarez, Cristina
Gutiérrez, Antonio
Moura, David S.
Hindi, Nadia
author Martín-Broto, Javier
author_facet Martín-Broto, Javier
Olarte-García, Alicia
Fernandéz-Rodríguez, Ricardo
Ribeiro Ferreira, Marta
Carrasco-García, Irene
Galvez-Montosa, Fernando
Rincón-Pérez, Inmaculada
Peinado-Serrano, Javier
Azinovic, Ignacio
Guzmán-Gómez, Laura
Salgado, Lurdes
Sevillano, Alberto
Ortega, Justo
Alvarez, Cristina
Gutiérrez, Antonio
Moura, David S.
Hindi, Nadia
author_role author
author2 Olarte-García, Alicia
Fernandéz-Rodríguez, Ricardo
Ribeiro Ferreira, Marta
Carrasco-García, Irene
Galvez-Montosa, Fernando
Rincón-Pérez, Inmaculada
Peinado-Serrano, Javier
Azinovic, Ignacio
Guzmán-Gómez, Laura
Salgado, Lurdes
Sevillano, Alberto
Ortega, Justo
Alvarez, Cristina
Gutiérrez, Antonio
Moura, David S.
Hindi, Nadia
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv PharmaMar
Martín-Broto, Javier [0000-0001-7350-6916]
Moura, David S. [0000-0002-6514-2419]
Hindi, Nadia [0000-0002-5864-762X]
Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]
dc.subject.none.fl_str_mv Durable response
Leiomyosarcoma
Soft tissue sarcomas
Trabectedin
topic Durable response
Leiomyosarcoma
Soft tissue sarcomas
Trabectedin
description © The Author(s), 2024. Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Sage and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
publishDate 2024
dc.date.none.fl_str_mv 2024
2024
2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
http://purl.org/coar/resource_type/c_6501
Publisher's version
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10261/360232
url http://hdl.handle.net/10261/360232
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.1177/17588359231225044
https://doi.org/10.1177/17588359231225044
Sí
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sage Publications
publisher.none.fl_str_mv Sage Publications
dc.source.none.fl_str_mv reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC
instname:Consejo Superior de Investigaciones Científicas (CSIC)
instname_str Consejo Superior de Investigaciones Científicas (CSIC)
reponame_str DIGITAL.CSIC. Repositorio Institucional del CSIC
collection DIGITAL.CSIC. Repositorio Institucional del CSIC
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869415962208370688
score 15,811543

Similares en LA Referencia